

Cemiplimab

Indication

Treatment of locally advanced or metastatic cutaneous squamous cell carcinoma when curative surgery or curative radiotherapy is not appropriate.

(NICE TA598)

ICD-10 codes

Codes with a prefix C44

Regimen details

Day	Drug	Dose	Route
1	Cemiplimab	350mg	IV infusion

Cycle frequency

21 days

Number of cycles

Treatment should be continued until unacceptable toxicity or disease progression, for a maximum of 2 years (35 3 weekly cycles).

Administration

Cemiplimab is administered in 100mL sodium chloride 0.9% over 30 minutes. It must be administered via an intravenous line containing a sterile, non-pyrogenic, low-protein binding, in-line or add-on filter (0.2 micron to 5 micron pore size).

Patients should be monitored for infusion related reactions, including nausea, pyrexia, abdominal pain, chills and flushing. For mild to moderate (Grade 1-2) reactions interrupt the infusion and recommence at a slower rate. For severe or life-threatening (Grade 3-4) reactions, permanently discontinue treatment.

Pre-medication

Nil

Emetogenicity

This regimen has low emetogenic potential

Additional supportive medication

Nil required routinely.

Extravasation

Cemiplimab is neutral (Group 1)

Investigations – pre first cycle

Investigation	Validity period (or as per local policy)
FBC	14 days
U+E (including creatinine)	14 days
LFT	14 days
Thyroid function	14 days
Calcium	14 days
Glucose	14 days
Cortisol	14 days

Investigations – pre subsequent cycles

Investigation	Validity period (or as per local policy)
FBC	72 hours
U+E (including creatinine)	72 hours
LFT	72 hours
Calcium	As clinically indicated
Thyroid function*	72 hours
Glucose*	72 hours
Cortisol*	72 hours

* every cycle for the first 24 weeks, then every other cycle.

Standard limits for administration to go ahead

If blood results not within range, authorisation to administer **must** be given by prescriber/ consultant.

Investigation	Limit
Neutrophil count	$\geq 1.0 \times 10^9/L$
Platelets	$\geq 75 \times 10^9/L$
Creatinine Clearance (CrCl)	$\geq 30\text{mL/min}$
Bilirubin	See below
ALT/AST	See below
Alkaline Phosphatase	See below

Dose modifications

Dose reductions are not recommended. Dosing delay or discontinuation may be required based on individual safety and tolerability.

- **Haematological toxicity**

Discuss with the consultant if:

WBC $< 2.0 \times 10^9/L$

Neutrophils $< 1.0 \times 10^9/L$

Platelets $< 75 \times 10^9/L$

- **Renal impairment**

No dose adjustment is recommended for patients with mild – moderate renal impairment. There is limited data for cemiplimab in patients with severe renal impairment CrCl $< 30 \text{ mL/min}$ – discuss with consultant.

- **Hepatic impairment**

No dose adjustment is recommended for patients with mild hepatic impairment. Cemiplimab has not been studied in patients with moderate or severe hepatic impairment.

- **Other toxicities**

Management of immune-related adverse reactions may require a dose delay or permanent discontinuation of

treatment and initiation of systemic high-dose corticosteroid or, in some cases, the addition of other immunosuppressive therapy. Dose reduction is not recommended.

Permanently discontinue treatment in patients with the following symptoms:

Toxicity – severe or life threatening	Definition	Action
Pneumonitis	Grade 3 or 4 or recurrent grade 2 pneumonitis	Treat with initial dose of 2 to 4 mg/kg/day prednisone or equivalent followed by a taper.
Colitis	Grade 4 or recurrent grade 3 colitis	Treat with initial dose of 1 or 2 mg/kg/day prednisone or equivalent followed by a taper.
Hepatitis	Grade ≥3 with AST or ALT > 5xULN Or total bilirubin > 3xULN	Treat with initial dose of 1 or 2 mg/kg/day prednisone or equivalent followed by a taper.
Skin	Grade 4 or confirmed Stevens Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN)	Treat with initial dose of 1 or 2 mg/kg/day prednisone or equivalent followed by a taper.
Immune-related skin reaction or other immune-related adverse reactions in patients with prior treatment with idelalisib.	Grade 3 or 4 (excluding endocrinopathies) or recurrent Grade 2.	Initiate symptomatic management immediately, including initial dose of 1 to 2 mg/kg/day prednisone or equivalent followed by a taper.
Nephritis	Grade 3 or 4	Treat with initial dose of 1 or 2 mg/kg/day prednisone or equivalent followed by a taper.
Other immune-related adverse reactions	<ul style="list-style-type: none"> – Grade 4 adverse reaction (excluding endocrinopathies) – Recurrent severe Grade 3 immune-related adverse reaction – Persistent Grade 2 or 3 immune-related adverse reactions lasting 12 weeks or longer (excluding endocrinopathies) – Inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks. 	

Withhold treatment in patients with the following symptoms:

Toxicity – severe or life threatening	Definition	Action
Pneumonitis	Grade 2	Withhold. Treat with initial dose of 1 to 2 mg/kg/day prednisone or equivalent followed by a taper. Resume if pneumonitis improves and remains at Grade 0 to 1 after corticosteroid taper to ≤ 10 mg/day prednisone or equivalent.
Colitis	Grade 2 or 3	Withhold. Treat with initial dose of 1 to 2 mg/kg/day prednisone or equivalent followed by a taper. Resume if colitis or diarrhoea improves and remains at Grade 0 to 1 after corticosteroid taper to ≤ 10 mg/day prednisone or equivalent.
Hepatitis	Grade 2 with AST or ALT >3 and ≤ 5 xULN or total bilirubin >1.5 and ≤ 3 xULN	Withhold. Treat with initial dose of 1 or 2 mg/kg/day prednisone or equivalent followed by a taper. Resume if hepatitis improves and remains at Grade 0 to 1 after corticosteroid taper to ≤ 10 mg/day prednisone or equivalent or returns to baseline AST or ALT after completion of corticosteroid taper.
Hypothyroidism	Grade 3 or 4	Withhold. Initiate thyroid hormone replacement as clinically indicated. Resume when hypothyroidism returns to Grade 0 to 1 or is otherwise clinically stable.
Hyperthyroidism	Grade 3 or 4	Withhold. Initiate symptomatic management as clinically indicated. Resume when hypothyroidism returns to Grade 0 to 1 or is otherwise clinically stable.
Hypophysitis	Grade 2-4	Withhold. Treat with initial dose of 1 or 2 mg/kg/day prednisone or equivalent followed by a taper and hormone replacement as clinically indicated. Resume if hypophysitis improves and remains at Grade 0 to 1 after corticosteroid taper to ≤ 10 mg/day prednisone or equivalent or is otherwise clinically stable.
Adrenal insufficiency	Grade 2-4	Withhold. Treat with initial dose of 1 or 2 mg/kg/day prednisone or equivalent followed by a taper and hormone replacement as clinically indicated. Resume if adrenal insufficiency improves and remains at Grade 0 to 1 after corticosteroid taper to ≤ 10 mg/day prednisone or equivalent or is otherwise clinically stable. Hormone (hydrocortisone) replacement should continue as required.

Type 1 diabetes	Grade 3 or 4	Withhold. Initiate treatment with anti-hyperglycaemics as clinically indicated. Resume when returns to Grade 0 to 1 or is otherwise clinically stable.
Skin	Grade 2 lasting longer than 1 week, Grade 3 or suspected Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)	Withhold Treat with initial dose of 1 or 2 mg/kg/day prednisone or equivalent followed by a taper. Resume if improves and remains at Grade 0 to 1 after corticosteroid taper to ≤ 10 mg/day prednisone or equivalent.
Immune-related skin reaction or other immune-related adverse reactions in patients with prior treatment with idelalisib.	Grade 2	Withhold. Initiate symptomatic management immediately, including initial dose of 1 to 2 mg/kg/day prednisone or equivalent followed by a taper. Resume if skin reaction or other immune-related adverse reaction improves and remains at Grade 0 to 1 after corticosteroid taper to ≤ 10 mg/day prednisone or equivalent.
Nephritis	Grade 2	Withhold Treat with initial dose of 1 or 2 mg/kg/day prednisone or equivalent followed by a taper. Resume if improves and remains at Grade 0 to 1 after corticosteroid taper to ≤ 10 mg/day prednisone or equivalent.
Other immune-related adverse reactions	Grade 3 clinical signs or symptoms of an immune-related adverse reaction not described above.	Withhold. Initiate symptomatic management. Resume if other immune-related adverse reaction improves and remains at Grade 0 to 1 after corticosteroid taper to ≤ 10 mg/day prednisone or equivalent.

Adverse effects - for full details consult product literature/ reference texts

- **Serious side effects**

Pneumonitis

Colitis

Hepatitis

Thyroid disorders

Hypophysitis

Adrenal insufficiency

Nephritis

Infusion related reactions

Vasculitis

ITP

Peripheral neuropathy, Guillain Barre syndrome, encephalitis

- **Frequently occurring side effects**

Skin disorders
Stomatitis
Diarrhoea
Fatigue
Arthralgia, arthritis
Decreased appetite
Hyperglycaemia
Abdominal pain
Anorexia

- **Other side effects**

Headache
Raised transaminases

Significant drug interactions – for full details consult product literature/ reference texts

Corticosteroids or immunosuppressants: use of systemic corticosteroids or immunosuppressants before starting cemiplimab, should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of the agent. However, systemic corticosteroids or other immunosuppressants can be used after starting cemiplimab to treat immune-related adverse reactions.

Additional comments

Patients must be provided with a Patient Alert Card before they start treatment.

Women of childbearing potential should use effective contraception during treatment with cemiplimab and for at least 4 months after the last dose of cemiplimab.

References

- National Institute for Health and Clinical Excellence TA384. Accessed 27 November 2019 via www.nice.org.uk
- Summary of Product Characteristics Cemiplimab (Bristol Myers Squibb) accessed 27 November 2019 via www.medicines.org.uk
- Migden, M et al ; PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma NEJM 2018 ; 379 : 341 - 351

Written/reviewed by: Dr A Challapalli (Consultant Oncologist, UHBristol NHS Trust)

Checked by: Sarah Murdoch (Lead Pharmacist, SW Clinical Network)

Authorised by: Dr J Braybrooke (Consultant Oncologist, SW Clinical Network)

Date: February 2020
